Antibacterial and Antivirulence Activity of Glucocorticoid PYED-1 against Stenotrophomonas maltophilia
Open Access
- 2 March 2020
- journal article
- research article
- Published by MDPI AG in Antibiotics
- Vol. 9 (3) , 105
Abstract
Stenotrophomonas maltophilia, an environmental Gram-negative bacterium, is an emerging nosocomial opportunistic pathogen that causes life-threatening infections in immunocompromised patients and chronic pulmonary infections in cystic fibrosis patients. Due to increasing resistance to multiple classes of antibiotics, S. maltophilia infections are difficult to treat successfully. This makes the search for new antimicrobial strategies mandatory. In this study, the antibacterial activity of the heterocyclic corticosteroid deflazacort and several of its synthetic precursors was tested against S. maltophilia. All compounds were not active against standard strain S. maltophilia K279a. The compound PYED-1 (pregnadiene-11-hydroxy-16α,17α-epoxy-3,20-dione-1) showed a weak effect against some S. maltophilia clinical isolates, but exhibited a synergistic effect with aminoglycosides. PYED-1 at sub-inhibitory concentrations decreased S. maltophilia biofilm formation. Quantitative real-time polymerase chain reaction (RT-qPCR) analysis demonstrated that the expression of biofilm- and virulence- associated genes (StmPr1, StmPr3, sphB, smeZ, bfmA, fsnR) was significantly suppressed after PYED-1 treatment. Interestingly, PYED-1 also repressed the expression of the genes aph (3′)-IIc, aac (6′)-Iz, and smeZ, involved in the resistance to aminoglycosides.Keywords
Funding Information
- Ministero dell’Istruzione, dell’Università e della Ricerca (PRIN2017 (Grant 2017SFBFER))
This publication has 50 references indexed in Scilit:
- The opportunistic pathogen Stenotrophomonas maltophilia utilizes a type IV secretion system for interbacterial killingPLOS Pathogens, 2019
- Cystic fibrosis related diabetes is not independently associated with increased Stenotrophomonas maltophilia infection: Longitudinal data from the UK CF RegistryJournal of Cystic Fibrosis, 2019
- Stenotrophomonas maltophilia as an Emerging Ubiquitous Pathogen: Looking Beyond Contemporary Antibiotic TherapyFrontiers in Microbiology, 2017
- Incident Stenotrophomonas maltophilia infection and lung function decline in cystic fibrosisPediatric Pulmonology, 2017
- Risk factors for mortality in patients with Stenotrophomonas maltophilia bacteremiaMedicine, 2016
- Chronic Stenotrophomonas maltophilia infection and mortality or lung transplantation in cystic fibrosis patientsJournal of Cystic Fibrosis, 2013
- Stenotrophomonas maltophilia – The most worrisome threat among unusual non-fermentative gram-negative bacilli from hospitalized patients: A prospective multicenter studyJournal of Infection, 2012
- Stenotrophomonas maltophilia: an Emerging Global Opportunistic PathogenClinical Microbiology Reviews, 2012
- Stenotrophomonas maltophilia: an emerging opportunist human pathogenThe Lancet Infectious Diseases, 2009
- Molecular epidemiology of Stenotrophomonas maltophilia in a university hospitalJournal of Hospital Infection, 2002